World Journal of Gastrointestinal Oncology最新文献

筛选
英文 中文
Early and late-onset colorectal cancer in African Americans during COVID-19. COVID-19期间非洲裔美国人的早发性和晚发性结直肠癌
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.105800
Lakshmi G Chirumamilla, Hassan Brim, Suryanarayana R Challa, Gholamreza Oskrochi, Mrinalini Deverapalli, Rumaisa Rashid, Mudasir Rashid, Farshad Aduli, Angesom Kibreab, Adeyinka Laiyemo, Zaki A Sherif, Nader Shayegh, Babak Shokrani, Rabia Zafar, John M Carethers, Hassan Ashktorab
{"title":"Early and late-onset colorectal cancer in African Americans during COVID-19.","authors":"Lakshmi G Chirumamilla, Hassan Brim, Suryanarayana R Challa, Gholamreza Oskrochi, Mrinalini Deverapalli, Rumaisa Rashid, Mudasir Rashid, Farshad Aduli, Angesom Kibreab, Adeyinka Laiyemo, Zaki A Sherif, Nader Shayegh, Babak Shokrani, Rabia Zafar, John M Carethers, Hassan Ashktorab","doi":"10.4251/wjgo.v17.i12.105800","DOIUrl":"10.4251/wjgo.v17.i12.105800","url":null,"abstract":"<p><strong>Background: </strong>The incidence of early-onset colorectal cancer (EOCRC, < 45 years of age at onset) is on the rise among adults, including African Americans (AA).</p><p><strong>Aim: </strong>To examine differences between EOCRC and late-onset colorectal cancer (LOCRC) among AA patients and any effect during coronavirus disease (COVID) by comparing data during pre-COVID (2015-2019) and the COVID era (2020-2023).</p><p><strong>Methods: </strong>We conducted a retrospective review of Howard University Hospital records from 2015 to 2023 for colorectal cancer patients that included demographics, clinicals, pathology, and colonoscopy records. A three-year interval analysis was performed to compare post-COVID era (2020-2023) to preceding years to discern temporal trends.</p><p><strong>Results: </strong>The study included 138 LOCRC and 13 EOCRC cases of which > 80% of patients were AA. Compared to pre-COVID, LOCRC cases increased in number from 55 to 83, and EOCRC cases increased from 6 to 7 during COVID. There was no change in mean age for LOCRC (64.7 years <i>vs</i> 65.3 years) but mean age increased for EOCRC (37.3 years <i>vs</i> 41.5 years). Males predominated in both groups particularly during the pandemic. More than 65% of LOCRC patient colonoscopies were for diagnostic purposes. Gastrointestinal bleeding as a colonoscopy indication and reduced bowel preparation quality were increased during the pandemic. EOCRC patients showed a shift from stage 4 (49.2%) to stage 2 (30%) and LOCRC patients staging trends changed from stage 4 (40%) to stage 3 (28.6%).</p><p><strong>Conclusion: </strong>We report increase in colorectal cancer cases during the COVID-19 era, especially among young AA males. EOCRC and LOCRC patients showed distal location predominance, most commonly in recto-sigmoid region. The decrease in staging or metastasis, which might be due to growing awareness and earlier detection among patients.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"105800"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating radiotherapy's impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab. 探讨放疗对贝伐单抗治疗胃肠道肿瘤患者肠道穿孔风险的影响。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.110621
Wei-Mei He, Wen-Si Li
{"title":"Investigating radiotherapy's impact on intestinal perforation risk in gastrointestinal tumor patients treated with bevacizumab.","authors":"Wei-Mei He, Wen-Si Li","doi":"10.4251/wjgo.v17.i12.110621","DOIUrl":"10.4251/wjgo.v17.i12.110621","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal tumors are among the most common and deadly cancers globally, with radiotherapy and bevacizumab being key treatment strategies. Radiotherapy uses high-energy radiation to target DNA, reducing tumor size and alleviating symptoms. Bevacizumab, a targeted therapy, inhibits angiogenesis and tumor growth, particularly in advanced gastrointestinal cancers. However, both treatments can cause adverse gastrointestinal effects, such as intestinal mucosal damage and perforation. While research on the risk of intestinal perforation has grown, the underlying mechanisms remain underexplored. This study aims to compare the incidence of intestinal perforation and survival rates in patients treated with radiotherapy combined with bevacizumab <i>vs</i> bevacizumab alone.</p><p><strong>Aim: </strong>To investigate the effect of radiotherapy on the risk of intestinal perforation in patients with colon cancer treated with bevacizumab.</p><p><strong>Methods: </strong>A total of 70 patients diagnosed with gastrointestinal malignancies admitted to our hospital from January 2023 to December 2024 were selected as research subjects. According to different treatment methods, 70 patients were divided into the bevacizumab only group (receiving bevacizumab treatment) and the bevacizumab + radiotherapy group (receiving radiotherapy combined with bevacizumab treatment), with 35 cases in each group. The two groups were compared in terms of clinical efficacy, incidence of intestinal perforation, serum tumor marker levels, overall survival and progression-free survival, levels of angiogenic factors, and adverse reactions.</p><p><strong>Results: </strong>Compared with the group treated with bevacizumab alone, the group treated with bevacizumab plus radiotherapy showed significant improvements in effective rate, overall survival, and progression-free survival (<i>P</i> < 0.05); the probability of intestinal perforation in the bevacizumab + radiotherapy group was 13.33%, while the probability of intestinal perforation in the bevacizumab group was 0. There was a statistically significant difference in the incidence of intestinal perforation between the two groups (<i>P</i> = 0.039). Following treatment, the levels of carbohydrate antigen (CA) 125, CA199, and CA153 in patients were significantly reduced (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Radiation therapy may increase the risk of intestinal perforation in colon cancer patients receiving bevacizumab treatment. In clinical applications, the risks of combined use of radiotherapy and bevacizumab should be fully considered and personalized treatment plans should be formulated.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"110621"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754297/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. 程序性死亡1抑制剂联合呋喹替尼、多西他赛治疗晚期结直肠癌的初步探讨。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.112548
Xian-Yang Meng, Yu-Mei Cai, Ning-Ning Sun, Wen-Hua Zhang, Rui-Xue Cui, Long Zhang, Cheng-Cheng Zheng, Zhen Sun, Wei-Xuan Luo, Feng-Wei Wang
{"title":"Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer.","authors":"Xian-Yang Meng, Yu-Mei Cai, Ning-Ning Sun, Wen-Hua Zhang, Rui-Xue Cui, Long Zhang, Cheng-Cheng Zheng, Zhen Sun, Wei-Xuan Luo, Feng-Wei Wang","doi":"10.4251/wjgo.v17.i12.112548","DOIUrl":"10.4251/wjgo.v17.i12.112548","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors have demonstrated significant efficacy in colorectal cancer (CRC) patients with microsatellite instability-high or deficient mismatch repair. However, their efficacy as monotherapy is limited in microsatellite stable/proficient mismatch repair (MSS/pMMR) subtypes.</p><p><strong>Aim: </strong>To provide an evidence-based rationale for optimizing later-line therapeutic strategies in advanced MSS/pMMR CRC.</p><p><strong>Methods: </strong>This study conducted a systematic retrospective analysis to evaluate the efficacy and safety of a triple-combination regimen comprising programmed death 1 inhibitors, fruquintinib and docetaxel administered as third-line therapy in 13 patients with advanced MSS/pMMR CRC.</p><p><strong>Results: </strong>Primary endpoints included progression-free survival and disease control rate. Intention-to-treat analysis showed median progression-free survival 7.0 months, median overall survival 18.5 months, disease control rate 61.5%, with manageable toxicity.</p><p><strong>Conclusion: </strong>Although this is a small-sample retrospective study, it preliminarily validates the synergistic effect of programmed death 1 inhibitors combined with fruquintinib and docetaxel in MSS/pMMR CRC, providing a novel strategy with translational significance for later-line treatment in advanced patients.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"112548"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognosis of intensive care unit patients with colorectal cancer. 结直肠癌重症监护病人的预后分析。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.114109
Yu-Ting Liao, Wen-Liang Zhu
{"title":"Prognosis of intensive care unit patients with colorectal cancer.","authors":"Yu-Ting Liao, Wen-Liang Zhu","doi":"10.4251/wjgo.v17.i12.114109","DOIUrl":"10.4251/wjgo.v17.i12.114109","url":null,"abstract":"<p><p>This letter provides commentary on the manuscript \"Intensive care unit outcomes and prognostic factors of colorectal cancer\". The study is the first to present multicenter data on the 90-day mortality of patients with colorectal cancer admitted to the intensive care unit, and identifies chemotherapy history, elective surgery, and conventional oxygen therapy as independent prognostic factors. We propose three refinements to enhance the study's clinical utility: Clarify chemotherapy details, including regimen and treatment phase, along with the surgical approach (curative <i>vs</i> palliative) and how preoperative tumor staging influences prognosis; elucidate the relationship between intensive care unit admission etiologies and prognosis; and incorporate colorectal cancer-specific biomarkers to optimize prognostic scoring systems. The study's core contribution is substantial, and refinement of the details will further enhance its clinical translational relevance.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"114109"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimized digital polymerase chain reaction enables detection of telomerase reverse transcriptase C228T mutation for prognostic assessment in hepatocellular carcinoma. 优化的数字聚合酶链反应能够检测端粒酶逆转录酶C228T突变用于肝细胞癌的预后评估。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.113289
Zulihumaer Aizimuaji, Nan Hu, Hai-Yang Li, Xi-Jun Wang, Sheng Ma, Ya-Ru Wang, Rui-Qi Zheng, Zhuo Li, Huan Zhao, Wei-Qi Rong, Ting Xiao
{"title":"Optimized digital polymerase chain reaction enables detection of telomerase reverse transcriptase C228T mutation for prognostic assessment in hepatocellular carcinoma.","authors":"Zulihumaer Aizimuaji, Nan Hu, Hai-Yang Li, Xi-Jun Wang, Sheng Ma, Ya-Ru Wang, Rui-Qi Zheng, Zhuo Li, Huan Zhao, Wei-Qi Rong, Ting Xiao","doi":"10.4251/wjgo.v17.i12.113289","DOIUrl":"10.4251/wjgo.v17.i12.113289","url":null,"abstract":"<p><strong>Background: </strong>Recurrence remains the leading cause of poor prognosis in hepatocellular carcinoma (HCC), particularly among patients infected with hepatitis B virus (HBV). The telomerase reverse transcriptase (TERT) promoter is the most frequently mutated site in HBV-related HCC; however, its prognostic significance is not fully established.</p><p><strong>Aim: </strong>To evaluate the prognostic impact of TERT promoter mutations and efficiency of digital polymerase chain reaction (dPCR).</p><p><strong>Methods: </strong>A total of 66 HBV-related HCC patients who underwent hepatectomy were enrolled in this study. DNA extracted from fresh tumor tissues was analyzed for TERT promoter mutations using Sanger sequencing and dPCR. The dPCR assay was optimized by adding 7-deaza-dGTP, CviQ1, and ethylenediaminetetraacetic acid to improve detection sensitivity. Concordance between methods was assessed, and nomogram survival prediction models were developed to evaluate prognostic value based on mutation status.</p><p><strong>Results: </strong>TERT promoter mutations were detected in 26/66 (39.39%) cases by Sanger sequencing and 30/66 (45.45%) by dPCR. The two methods showed high concordance (93.939%, <i>κ</i> = 0.876), with dPCR demonstrating 100% sensitivity and 90% specificity. Patients harboring TERT promoter mutations exhibited reduced overall survival and higher recurrence risk. Nomogram models successfully distinguished mutant from non-mutant cases for both overall survival (C-index: 0.7651) and disease-free survival (C-index: 0.6899).</p><p><strong>Conclusion: </strong>TERT promoter mutation predicts poor prognosis in HBV-related HCC and serves as a biomarker for risk stratification. Optimized dPCR outperforms Sanger sequencing, and nomograms with TERT status guide precision therapy.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113289"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of citrullinated glial fibrillary acidic protein in predicting outcomes in hepatocellular carcinoma. 瓜氨酸化胶质原纤维酸性蛋白预测肝癌预后的临床意义。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.110877
Yoon Ah Cho, Dong Woo Shin, Mo-Jong Kim, Ji-Won Park, Ji-Young Choe, Jung-Woo Lee, Sung-Hoon Moon, Akihito Ishigami, Eun Kyoung Choi, Sung-Eun Kim
{"title":"Clinical significance of citrullinated glial fibrillary acidic protein in predicting outcomes in hepatocellular carcinoma.","authors":"Yoon Ah Cho, Dong Woo Shin, Mo-Jong Kim, Ji-Won Park, Ji-Young Choe, Jung-Woo Lee, Sung-Hoon Moon, Akihito Ishigami, Eun Kyoung Choi, Sung-Eun Kim","doi":"10.4251/wjgo.v17.i12.110877","DOIUrl":"10.4251/wjgo.v17.i12.110877","url":null,"abstract":"<p><strong>Background: </strong>Citrullination is a post-translational modification mediated by calcium-dependent peptidylarginine deiminases that results in notable changes in protein structure and function. Glial fibrillary acidic protein (GFAP), which is highly vulnerable to peptidylarginine deiminases-mediated modification, has been found to be elevated in activated hepatic stellate cells, with GFAP-positive hepatic stellate cells and myofibroblasts accumulating within and around areas of hepatic fibrosis. Although recent studies have shown that the expression of citrullinated GFAP (cit-GFAP) increases during hepatic fibrosis, its expression pattern and functional roles in hepatocellular carcinoma (HCC) remain unclear.</p><p><strong>Aim: </strong>To determine whether cit-GFAP expression influences the recurrence and survival of patients undergoing hepatic resection for HCC.</p><p><strong>Methods: </strong>We retrospectively analyzed 169 patients with HCC who underwent hepatic resection. Based on the immunohistochemical staining of resected specimens, the enrolled patients were stratified into two groups according to cit-GFAP expression: Low (-/1 +) or high (2 +/3 +) levels of expression. Kaplan-Meier survival curves were constructed to assess overall survival and recurrence-free survival, and comparisons between groups were performed using the log-rank test.</p><p><strong>Results: </strong>The median follow-up duration was 33 months (range, 1-183). High cit-GFAP expression, identified in 81 patients (48.2%), was significantly associated with male sex, hepatitis B virus positivity, and higher Edmonson-Steiner grade. No associations were found between age, diabetes, hypertension, cirrhosis, Child-Pugh classification, major portal vein invasion, hematological or biochemical parameters, tumor size, or number. Patients exhibiting high cit-GFAP expression demonstrated significantly poorer overall survival. Multivariate Cox analysis identified large tumor size (hazard ratio: 2.967; 95% confidence interval: 1.097-8.024; <i>P =</i> 0.032) and high cit-GFAP expression (hazard ratio: 2.753; 95% confidence interval: 1.015-7.464; <i>P</i> = 0.047) as independent predictors of poor postoperative survival. Although recurrence rates were high in patients with high cit-GFAP expression, the difference was not statistically significant.</p><p><strong>Conclusion: </strong>Following curative resection in patients with HCC, high cit-GFAP expression may serve as a potential prognostic biomarker, although further validation through independent cohort studies is warranted.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"110877"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomal miR-191 promotes colorectal cancer progression by inducing M2 macrophage polarization and inhibiting ferroptosis. 外泌体miR-191通过诱导M2巨噬细胞极化和抑制铁下垂促进结直肠癌进展。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.113524
Qing-Yun Zhao, Shou-Jiang Wei
{"title":"Exosomal miR-191 promotes colorectal cancer progression by inducing M2 macrophage polarization and inhibiting ferroptosis.","authors":"Qing-Yun Zhao, Shou-Jiang Wei","doi":"10.4251/wjgo.v17.i12.113524","DOIUrl":"10.4251/wjgo.v17.i12.113524","url":null,"abstract":"<p><strong>Background: </strong>Multiple exosomal microRNAs were reported to have a significant role in colorectal cancer (CRC) cells. The function and mechanism of exosomal miR-191 in CRC have not been clearly elucidated.</p><p><strong>Aim: </strong>To explore the roles of miR-191 in CRC.</p><p><strong>Methods: </strong>Supernatant exosomes from CRC cells were extracted and identified. After coculture, macrophage polarization was determined using flow cytometry for the markers cluster of differentiation (CD) 68 and CD163, enzyme-linked immunosorbent assay for the cytokines interleukin (IL)-4 and IL-10, western blotting for chitinase-like protein 3 and arginase-1 expression, and immunofluorescent staining for 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate. Reactive oxygen species (ROS) level, ferroptosis-related proteins (<i>SLC7A11</i> and <i>GPX4</i>), and apoptosis were determined with flow cytometry, western blotting, and TUNEL staining. We performed in vivo experiments to determine the function of exosomal miR-191 and M2 macrophage polarization.</p><p><strong>Results: </strong>We successfully isolated exosomes from CRC cells. Inhibition of miR-191 in CRC cells suppressed M2 polarization of macrophages. After coculture of macrophages, inhibition of miR-191 induced ROS production, ferroptosis, and apoptosis of CRC cells. Silencing of exosomal miR-191 from CRC cells prevented M2 polarization of macrophages, and weakened CRC development by inducing ferroptosis. Exosomal miR-191 accelerated cancer progression in CRC nude mice by promoting M2 polarization of macrophages.</p><p><strong>Conclusion: </strong>Inhibition of exosomal miR-191 attenuated CRC progression by inducing ferroptosis in macrophages. This study revealed a novel mechanism by which exosomal miR-191 modulates the tumor microenvironment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113524"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma. 淋巴细胞与c反应蛋白比率作为一种新的炎症生物标志物:作为胆管癌独立预后因素的验证和临床相关性
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.113853
Fan Xiao, De-Hua Zhou, Guo-Wei Liu, Chao-Wei Lin, Zi-You Wu, Hua Yu, Wei Gong, Wei-Feng Tan
{"title":"Lymphocyte to C-reactive protein ratio as a novel inflammatory biomarker: Validation and clinical relevance as an independent prognostic factor in cholangiocarcinoma.","authors":"Fan Xiao, De-Hua Zhou, Guo-Wei Liu, Chao-Wei Lin, Zi-You Wu, Hua Yu, Wei Gong, Wei-Feng Tan","doi":"10.4251/wjgo.v17.i12.113853","DOIUrl":"10.4251/wjgo.v17.i12.113853","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory cytokines are associated with cancer prognosis, but their specific role in cholangiocarcinoma remains poorly understood. The lymphocyte to C-reactive protein ratio (LCR), a novel inflammatory-nutritional biomarker, has demonstrated predictive value in gastrointestinal cancers; however, its clinical relevance in cholangiocarcinoma has not been investigated.</p><p><strong>Aim: </strong>To validate the LCR as an independent prognostic factor for overall survival (OS), surgical site infection (SSI), and length of hospital stay in patients with resectable cholangiocarcinoma.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 76 patients with cholangiocarcinoma who underwent radical surgery between 2008 and 2013. The preoperative LCR was calculated as the lymphocyte count divided by C-reactive protein level, using a cutoff value of 180. Univariate and multivariate logistic regression analyses were performed to evaluate factors associated with SSI and hospitalization duration, while Kaplan-Meier survival curves and Cox proportional hazards models were used to assess predictors of OS.</p><p><strong>Results: </strong>Patients in the low LCR group was significantly associated with several adverse clinical outcomes: A shorter median OS (14.93 months <i>vs</i> 46.67 months; <i>P</i> = 0.022); a 4.5-fold increased risk of prolonged hospitalization (<i>P</i> = 0.007); and a higher incidence of SSI (odds ratio = 4.41, <i>P</i> = 0.045). Multivariate analysis confirmed that LCR was an independent predictor of OS [hazard ratio (HR) = 3.204, <i>P</i> = 0.002], SSI, and hospitalization duration. Additionally, R0 resection (HR = 3.546, <i>P</i> = 0.002) and advanced tumor-node-metastasis stage (HR = 2.016, <i>P</i> = 0.035) were identified as independent prognostic factors for OS.</p><p><strong>Conclusion: </strong>In this retrospective study, preoperative LCR is a cost-effective and practical biomarker that independently predicts OS, postoperative complications, and hospitalization duration in patients with resectable cholangiocarcinoma, thereby facilitating more precise patient stratification.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113853"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic significance of preoperative C-reactive protein-triglyceride-glucose index in long-term outcomes after radical gastrectomy for gastric cancer. 术前c反应蛋白-甘油三酯-葡萄糖指数对胃癌根治术后远期预后的影响
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.113976
Qiu-Lin Hao, Zhi-Yuan Yao, Yu-Meng Shen, Zheng-Yu Li, Hao-Chun Gao, Xiao-Yu Hong, Geng-Chen Li, Chao Gao
{"title":"Prognostic significance of preoperative C-reactive protein-triglyceride-glucose index in long-term outcomes after radical gastrectomy for gastric cancer.","authors":"Qiu-Lin Hao, Zhi-Yuan Yao, Yu-Meng Shen, Zheng-Yu Li, Hao-Chun Gao, Xiao-Yu Hong, Geng-Chen Li, Chao Gao","doi":"10.4251/wjgo.v17.i12.113976","DOIUrl":"10.4251/wjgo.v17.i12.113976","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Gastric cancer, a globally prevalent malignant tumor, continues to exhibit high incidence and mortality rates. Although radical gastrectomy remains the primary treatment for this disease, postoperative complications frequently arise, negatively impacting short-term recovery and significantly reducing patients' quality of life. In this context, accurately predicting the risk of postoperative recurrence and metastasis, coupled with targeted interventions, could substantially improve patient outcomes. The C-reactive protein-triglyceride-glucose index (CTI), a composite biomarker that integrates metabolic disturbances and systemic inflammation, has garnered increasing attention in oncology. The prognostic nutritional index (PNI), a composite measure based on serum albumin and peripheral blood lymphocyte count, is used to evaluate both the nutritional status and systemic immune function of patients. In recent years, both the CTI and PNI have demonstrated significant prognostic value in predicting tumor outcomes, assessing treatment responses, and formulating personalized treatment strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To investigate whether the combined inflammation and insulin resistance marker, the CTI, can serve as a prognostic indicator for patients undergoing radical gastrectomy for gastric cancer. Additionally, it seeks to develop a predictive model by incorporating the PNI alongside CTI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective study included a total of 300 patients who underwent radical gastrectomy. The patients were classified into high and low CTI groups based on their CTI index. Cox proportional hazards regression analysis was performed to identify independent prognostic factors influencing overall survival (OS) and disease-free survival (DFS), and two nomogram models were developed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of the included patients, 131 had a high CTI and 169 had a low CTI. The DFS period of the low CTI group was significantly longer than that of the high CTI group. The number of postoperative adjuvant treatments, T stage, N stage, CTI, and PNI were identified as independent prognostic factors for DFS. The hazard ratio for CTI was 2.07 (95% confidence interval: 1.36-3.17, &lt;i&gt;P&lt;/i&gt; &lt; 0.001). In terms of OS, the OS period of the low CTI group was significantly longer than that of the high CTI group. Whether adjuvant treatment was administered, T stage, CTI, and PNI were independent prognostic factors for OS. The hazard ratio for CTI was 2.47 (95% confidence interval: 1.44-4.23, &lt;i&gt;P&lt;/i&gt; = 0.001). The nomogram models for OS and DFS further emphasized the importance of CTI as a key predictor of patient prognosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;CTI is a long-term prognostic indicator for the outcome of radical gastrectomy for gastric cancer. Patients with lower CTI values have a better prognosis. The prediction models constructed by combining CTI with PNI has good predictive ability for DFS","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113976"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of multimodal fusion technology in early recurrence prediction and pathological analysis of hepatocellular carcinoma. 多模式融合技术在肝细胞癌早期复发预测及病理分析中的应用。
IF 2.5 4区 医学
World Journal of Gastrointestinal Oncology Pub Date : 2025-12-15 DOI: 10.4251/wjgo.v17.i12.114037
Li-Hong Huang, Yi-Jing Fang, Xiao-Jun Zheng, Ce Huang, Chang-Lu Li, Bin Yu, Meng-Jie Huang, Shi-Ji Qin, De-You Huang, De-Wei Lu
{"title":"Application of multimodal fusion technology in early recurrence prediction and pathological analysis of hepatocellular carcinoma.","authors":"Li-Hong Huang, Yi-Jing Fang, Xiao-Jun Zheng, Ce Huang, Chang-Lu Li, Bin Yu, Meng-Jie Huang, Shi-Ji Qin, De-You Huang, De-Wei Lu","doi":"10.4251/wjgo.v17.i12.114037","DOIUrl":"10.4251/wjgo.v17.i12.114037","url":null,"abstract":"<p><strong>Background: </strong>Early recurrence is an important factor affecting the prognosis of hepatocellular carcinoma (HCC), but its preoperative prediction remains challenging.</p><p><strong>Aim: </strong>To explore the value of a multimodal interpretable fusion model combining computed tomography (CT) habitat imaging (HI), radiomics, and clinical features in predicting early recurrence of HCC and analyze its correlation with pathological indicators.</p><p><strong>Methods: </strong>The 191 HCC patients were categorized into early recurrence and non-early recurrence groups based on postoperative follow-up outcomes, and randomly divided into training and testing sets in a 7:3 ratio. Based on CT arterial phase and clinical data, the habitat model, radiomics model, clinical model, and fusion model were constructed and compared for their predictive ability in early recurrence of HCC. For the optimal model, SHapley Additive exPlanations (SHAP) analysis was performed to evaluate the contribution of different features in the model, and the correlation between HI and radiomics features with tumor microvascular invasion (MVI), Ki67 expression, GPC-3 expression, and pathological grading was analyzed.</p><p><strong>Results: </strong>The fusion model demonstrated the best performance in predicting early recurrence of HCC, achieving the area under the curve of 0.933 on the validation set. The decision curve analysis curve indicated that the fusion model yielded the highest clinical net benefit. SHAP analysis provided valuable insights into explaining the fusion model's prediction of early HCC recurrence. Correlation analysis revealed significant associations between certain radiomics and Habitat features and pathological indicators such as MVI and Ki-67 expression in HCC.</p><p><strong>Conclusion: </strong>An interpretable fusion model integrating clinical, radiomic, and habitat features can assist clinicians in identifying early postoperative recurrence of HCC, offering significant potential for prognosis prediction and clinical management.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"114037"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书